Verici Dx PLC - Cardiff, Wales-based developer of advanced clinical diagnostics for organ transplants - Completes second biennial inspection of its clinical laboratory, accredited by the College of American Pathologists. Verici says the inspection, passed with no deficiencies, shows its ‘commitment to compliance and maintaining excellence in daily clinical laboratory operations according to CAP requirements’. Adds: ‘By continuing to follow these strict CAP guidelines and pass CAP accreditation audits, Verici Dx can consistently provide reliable test results under its quality management system and further improve patient health.’
Current share price: 0.85 pence, closed down 0.6% in London on Wednesday
12-month change: down 75%
Copyright 2025 Alliance News Ltd. All Rights Reserved.
